The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Exciting agents and treatment approaches emerging in the field of myelofibrosis
Mary Frances McMullin, MD, Queen’s University, Belfast, UK, shares insights into the emerging agents and therapeutic approaches for patients with myelofibrosis (MF). Newer-generation JAK inhibitors momelotinib and pacritinib have shown therapeutic promise, and combination therapies, such as BET inhibitor and JAK inhibitor combinations, are being explored. Additionally, Prof. McMullin details the ongoing FEDORA clinical trial (ISRCTN88102629), a prospective, open-label, Phase II investigation evaluating the efficacy of the selective JAK2 inhibitor fedratinib, given in combination with ROPEG-IFN-2β, a long-acting interferon. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: Novartis, BMS, GSK; Speaker Bureau: Novartis, GSK, Incyte; Clinical Trial Support: BMS.
